STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · no price filed
What the filings say about SCTX
Insiders, 180 days
+$71.3M net bought
6 buyers
Activist stakes (13D), 180 days
3 filings
Largest: 16.4% of the class
Scribe Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Scribe Therapeutics, Inc. insiders bought a net $71.3M of stock across 8 Form 4 purchases and sales, with 6 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 77.0% of the 3,030,983 shares held after it.
5 other insiders bought within 30 days.
Insider activity: Director Aghazadeh Behzad bought about $35.0M of SCTX on Jul 24, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days.
8 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
SCTX ranks highest on insider conviction (98th percentile) and growth (17th), and lowest on risk and compliance (2nd), among Pharma & Biotech peers.
Growth
17
Inputs
Revenue growth, YoY-60.8% · 17 pct, sector of 505
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
98
Inputs
Net Form 4 buying (codes P and S), 180d$71.3M · 98 pct, sector of 428
Insider buyers, 180d6 · 97 pct, sector of 437
Risk and compliance
2
Inputs
Short interest, % of float+35.8% · 2 pct, sector of 813
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Institutional and government, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SCTX filings, in plain words
Are Scribe Therapeutics insiders buying or selling SCTX?
In the 180 days to 2026-10-27, Scribe Therapeutics insiders were net buyers, a net $71.3M across purchases and sales reported on Form 4, by 6 buyers.
Read the full summary
In the 180 days to 2026-10-27, Scribe Therapeutics insiders were net buyers of SCTX, a net $71.3M across purchases and sales reported on Form 4 by 6 buyers. Most of that figure, $41.3M, came from a holder of 10% or more rather than an officer or director. 6 insiders reported purchases in that window. 3 activist Schedule 13D filings in the last 180 days declared an intent to influence the company, the largest for 16.4% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.
